Type-II/JJ
estrogen/NN
binding/NN
sites/NNS
in/IN
a/DT
lymphoblastoid/JJ
cell/NN
line/NN
and/CC
growth-inhibitory/JJ
effect/NN
of/IN
estrogen/NN
,/,
anti-estrogen/NN
and/CC
bioflavonoids/NNS
./.

Type-II/JJ
estrogen-binding/JJ
sites/NNS
(/(
type-II/JJ
EBS/NNS
)/)
have/VBP
been/VBN
demonstrated/VBN
in/IN
the/DT
human/JJ
lymphoblastoid/JJ
cell/NN
line/NN
IM-9/NN
using/VBG
a/DT
whole-cell/JJ
assay/NN
with/IN
(/(
6,7-3H/NN
)/)
estradiol/NN
(/(
3H-E2/NN
)/)
as/IN
tracer/NN
./.
=====
Competition/NN
analysis/NN
showed/VBD
that/IN
the/DT
anti-estrogen/JJ
tamoxifen/NN
and/CC
the/DT
flavonoids/NNS
quercetin/NN
and/CC
rutin/NN
competed/VBD
for/IN
(3H)-E2/NN
binding/NN
to/TO
type-II/JJ
EBS/NNS
./.
=====
Growth/NN
experiments/NNS
demonstrated/VBD
that/IN
diethylstilbestrol/NN
(/(
DES/NN
)/)
tamoxifen/NN
(/(
TAM/NN
)/)
,/,
quercetin/NN
and/CC
rutin/NN
exerted/VBD
a/DT
reversible/JJ
dose-dependent/JJ
inhibition/NN
of/IN
cell/NN
proliferation/NN
in/IN
the/DT
range/NN
of/IN
concentrations/NNS
between/IN
10/CD
nM/NN
and/CC
10/CD
microM/NN
./.
=====
The/DT
relative/JJ
binding/NN
affinity/NN
of/IN
quercetin/NN
,/,
rutin/NN
,/,
DES/NN
and/CC
TAM/NNP
for/IN
type-II/JJ
EBS/NNS
correlated/VBD
well/RB
with/IN
their/PRP$
potency/NN
as/IN
cell/NN
growth/NN
inhibitors/NNS
./.
=====
Moreover/RB
,/,
hesperidin/NN
,/,
a/DT
flavonoid/NN
which/WDT
does/VBZ
not/RB
bind/VB
to/TO
type-II/JJ
EBS/NNS
,/,
was/VBD
ineffective/JJ
in/IN
inhibiting/VBG
cell/NN
growth/NN
./.
=====
Cell-cycle/JJ
analysis/NN
showed/VBD
that/IN
the/DT
growth-inhibitory/JJ
effect/NN
of/IN
DES/NN
,/,
TAM/NN
or/CC
quercetin/NN
was/VBD
due/JJ
to/TO
a/DT
blocking/NN
effect/NN
in/IN
the/DT
G0-G1/JJ
phases/NNS
./.
=====
Our/PRP$
results/NNS
suggest/VBP
that/IN
high/JJ
estrogen/NN
and/CC
anti-estrogen/JJ
concentrations/NNS
and/CC
flavonoids/NNS
may/MD
regulate/VB
IM-9/NN
cell/NN
growth/NN
through/IN
a/DT
common/JJ
mechanism/NN
involving/VBG
a/DT
binding/NN
interaction/NN
with/IN
type-II/JJ
EBS/NNS
./.